Patent · US Active

Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling

US11725055B2 · kind B2 · utility

0Cited by
1References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 6, 2020
Grant dateAug 15, 2023
Priority date
Expiry dateJan 21, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.